Cardiac patients diagnosed with “broken heart syndrome” are twice as likely to run into clinical complications during treatment if they have a history of cancer, Italian researchers reported this week at the ESC Congress in Munich.

Research presented this week at the European Society of Cardiology Congress in Munich suggests a new treatment may be emerging for transthyretin amyloid cardiomyopathy—a condition previously thought to be rare and untreatable.

Oregon’s only heart transplant program has suspended operations for at least two weeks after three cardiologists either left or announced plans to leave Oregon Health & Science University, The Oregonian reported Aug. 27.

Although heart failure researchers have made strides in enrolling more racial and ethnic minorities in clinical trials, women and older patients remain underrepresented, according to a systematic review published in JAMA Cardiology.

A new study in JAMA Cardiology uncovered a set of genetic variants that are almost exclusive to people of African ancestry and may explain their higher risk of adverse events related to dilated cardiomyopathy (DCM).

The FDA on Aug. 17 sent a letter warning cardiologists about high mortality and stroke rates associated with the Temporary Total Artificial Heart (TAH-t) Companion 2 Driver System during a post-approval study.

Originally thought to be a benign condition, Takotsubo syndrome is associated with long-term outcomes similar to acute coronary syndrome (ACS), researchers reported in the Journal of the American College of Cardiology. And in cases where Takotsubo syndrome (TTS) is triggered by physical events, prognosis is even worse.

Japanese researchers believe they’ve identified a genetic risk marker that could pinpoint which people with atrial fibrillation (AFib) are at risk of developing tachycardia-induced cardiomyopathy.